24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
U.S. Coronavirus Cases Near 3 Million as Hospitals in Sun Belt Fill Up With PatientsAHA News: Months After Infection, Many COVID-19 Patients Can't Shake IllnessCoronavirus Ups Anxiety, Depression in the LGBTQ CommunityMajor Medical Groups Urge Americans to Wear Face MasksBlack Patients Fare Worse After AngioplastyHow Immune System Fights COVID-19 May Be Key to Vaccine SuccessWill the COVID-19 Pandemic Leave a Mental Health Crisis in Its Wake?New U.S. Coronavirus Cases Hit Another HighMultiple Surgeries for Cleft Lip, Palate Won't Cause Major Psychological DamageHIV May Not Worsen COVID-19 OutlookU.S. Coronavirus Hospitalizations Spiking in South, WestAHA News: To Everything There Is a Season, Including Heart DiseaseAsthma, Allergies Plus Pandemic May Pose 4th of July ChallengesStroke Appears 8 Times More Likely With COVID Than With FluCOVID-19 Death Risk Twice as High in New York City as Some CountriesFireworks Are Bad News for Your LungsScientists Find Source of COVID ClotsNew U.S. Coronavirus Cases Top 50,000 as More States Slow Reopening PlansNumbers of Non-COVID-19 Deaths Up During PandemicNo Good Evidence on Accuracy of Coronavirus Antibody Tests: StudyAHA News: COVID-19 Pandemic Brings New Concerns About Excessive DrinkingMuscle Relaxants for Back Pain Are Soaring: Are They Safe?Trauma of Racism Fuels High Blood Pressure Among Black Americans: StudyCOVID-19 Blood Test Might Predict Who Will Need a VentilatorWhat's the Best DIY Face Mask Against COVID-19?Deep Brain Stimulation May Slow Parkinson's, Study FindsU.S. Could See 100,000 New Cases of COVID-19 Each Day, Fauci SaysGlobally, COVID-19 Cases May Stretch Far Beyond Official Numbers: StudyFBI: Beware of Scammers Selling Fake COVID-19 Antibody TestsAHA News: Sadness and Isolation of Pandemic Can Make Coping With Grief HarderVaping-Related Lung Injuries Still Happening -- And May Look Like COVID-19Most With Coronavirus Not Sure How They Caught It: CDCDon't Get Sick While Swimming This SummerAmid Pandemic, Too Many Americans Are Hesitating to Call 911Mask Up! Don't Let Down Your Guard Against COVID-19Wildfire Smoke Causes Rapid Damage to Your Health: StudyCOVID Drug Remdesivir Could Cost Up to $3,120 Per Patient, Maker SaysIntestinal Illness Spurs Recall of Bagged Salads Sold at Walmart, AldiCOVID Threatens the 3 out of 4 Americans Who Can't Work From HomeHispanic Americans Being Hit Hard By COVID-19Global Coronavirus Cases Pass 10 Million as U.S. Struggles With Surge in InfectionsStarted Early, Drug Combo Eases Fatigue of Rheumatoid Arthritis: StudyIs 'Pooled' Coronavirus Testing the Next Step for America?U.S. Coronavirus Task Force Warns of Rising Case Numbers, Especially Among YoungWho's at Highest Risk From COVID-19? CDC Updates Its ListStroke, Confusion: COVID-19 Often Impacts the Brain, Study ShowsPromising Results Mean Coronavirus Vaccine Trial Could Start by AugustWhen Can Sports Fans Safely Fill Stadiums Again?Coronavirus Baby Boom? Survey Says Maybe NotCOVID-19 Typically Mild for Babies: Study
Questions and AnswersLinks
Related Topics

Diabetes

FDA Approves IV Artesunate for Severe Malaria


HealthDay News
Updated: May 27th 2020

new article illustration

WEDNESDAY, May 27, 2020 (HealthDay News) -- Intravenous (IV) artesunate received approval from the U.S. Food and Drug Administration to treat adults and children with severe malaria, the agency announced Tuesday.

This approval marks the first for severe malaria since the marketing of quinine was discontinued in early 2019. Before the current approval, U.S. patients with severe malaria and those with uncomplicated malaria who were not able to take oral medications were treated with IV artesunate under an investigational new drug protocol through the FDA Expanded Access program.

About 2,000 cases of malaria are diagnosed in the United States each year, and about 300 of those cases are severe, according to data from the U.S. Centers for Disease Control and Prevention. The FDA notes that IV artesunate treatment for severe malaria should always be followed by a complete treatment course of an oral antimalarial regimen.

Approval of IV artesunate for severe malaria was based on two randomized controlled trials in Asia and Africa. In the trial in Asia, 1,461 patients, including 202 patients younger than 15 years, received IV artesunate or quinine. The African trial included 5,425 severe malaria patients younger than 15 years who were randomly assigned to treatment with artesunate or quinine. In both studies, fewer hospitalized patients treated with artesunate died compared with those treated with quinine. The most commonly reported adverse reactions in the trial in Asia included acute renal failure requiring dialysis, hemoglobinuria, and jaundice. The FDA notes that the safety profile in the African study was similar.

Approval was granted to Amivas.

More Information